Chauhan et al. [24] have pointed out that about 69% of SCLC patients have a higher serum NSE level, and the changes in this index are related to the occurrence of multiple tumors such as medullary thyroid carcinoma, neuroblastoma, and melanoma. The gene discussed is ENO2; the disease is melanoma.